Eicher Motors: Jefferies sees 22% upside potential; retains Buy with target at Rs 4150 Jefferies has retained a ‘Buy’ rating for Eicher Motors with a revised price target of Rs 4,150. This revised target sees a 22% upside target. The share price of Eicher Motors soared nearly 4% intra-day following this upside revision. “We believe time is ripe to buy EIM given alleviating competitive concerns, along with tailwinds of 2W demand recovery, industry premiumization and exports. We retain Buy and now prefer TVSL/Eicher over Bajaj Auto/HMCL in two-wheelers,” Jefferies explained in the report. Eicher Motors’ market capitalization stands at 95,346.93 crore on the NSE. The P/E ratio is 29.95, and the dividend yield is 1.05. The stock price of Eicher Motors gained 1.4% in the last one week, 4.2% in the last one month and a whopping 19.6% in the last 6 months, while it fell 5.7% in the last one year. The stock hit its 52-week high of Rs 3,889.65 on November 1, 2022, while it hit a 52-week low of Rs 2,836 on March 28, 2023, on the NSE. “We retain Buy on Eicher with revised PT of Rs 4,150 (earlier Rs 4,000), valuing RE at 25x FY25E PE (earlier 24x) and commercial vehicle business at 5.5x FY25E PB. We see potential for RE multiples to expand if it is able to largely protect its market share in the ongoing most-formidable phase of competition,” said the report.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.